Beyond Air (NASDAQ:XAIR – Get Free Report) and Accuray (NASDAQ:ARAY – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Valuation & Earnings
This table compares Beyond Air and Accuray”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beyond Air | $2.34 million | 14.21 | -$60.24 million | ($1.41) | -0.31 |
| Accuray | $446.55 million | 0.56 | -$15.55 million | ($0.05) | -49.00 |
Accuray has higher revenue and earnings than Beyond Air. Accuray is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Analyst Recommendations
This is a breakdown of recent ratings for Beyond Air and Accuray, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beyond Air | 0 | 1 | 3 | 1 | 3.00 |
| Accuray | 0 | 0 | 2 | 0 | 3.00 |
Beyond Air currently has a consensus target price of $3.67, indicating a potential upside of 737.71%. Accuray has a consensus target price of $9.00, indicating a potential upside of 267.35%. Given Beyond Air’s higher possible upside, equities research analysts clearly believe Beyond Air is more favorable than Accuray.
Institutional and Insider Ownership
31.5% of Beyond Air shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 20.1% of Beyond Air shares are held by insiders. Comparatively, 4.2% of Accuray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Beyond Air and Accuray’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beyond Air | -2,369.17% | -227.29% | -106.51% |
| Accuray | -0.96% | -9.75% | -0.93% |
Summary
Accuray beats Beyond Air on 8 of the 14 factors compared between the two stocks.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
About Accuray
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
